No, it’s not important.

It’s more than that. It’s .

Across the pharma world, the alignment to guidelines and rules set out by the regulatory authorities, and indeed the often even stricter requirements laid down by clients themselves must be not only met but exceeded in order to deliver success.

With full-service companies such as QUINTA-ANALYTICA operating under three practices, GMP, GLP, and GCP, the breadth of adherence is even greater.

This critical role, that underpins every modern pharmaceutical company, falls on the shoulders of the Quality Assurance team and who despite the challenges of the past year continued to meet their obligations and continue to deliver their high-quality services to both clients audits, and indeed the state authorities inspections in both the human and veterinary drugs areas.

As the slow return to normality starts, and the number of audits returning to the more usual 25-30 per annum, Quinta’s QA team are excited to move away from the remote audits of 2020, and back to the in-person visits whereby they can demonstrate the transparency and excellence that Quinta’s whole team deliver day in, day out.

Ready to start your next project? Quinta are here to assist.

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.